ONWARD Medical N.V., specializing in neurotechnologies, announces that Portzamparc – BNP Paribas Group has started covering its stock. This coverage comes with a buy recommendation and a target price set at EUR 10.20 per share. This decision follows the market approvals of the ARC-EX® system in the United States and Europe, marking a significant milestone for ONWARD in its commercial development.
Strategic Developments
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
According to Dave Marver, CEO of ONWARD Medical, the year 2025 is pivotal for the company, with not only the commercial authorization of the ARC-EX® system but also the planned launch of the first pivotal study for the implantable ARC-IM® platform. The company continues to strengthen its position in the field of brain-computer interface (BCI) assisted mobility, which could enhance its leadership in this emerging sector.
Analyst Confidence
The initiation note from Portzamparc, published on October 7, 2025, brings the number of banking institutions covering ONWARD Medical's stock to five. All these institutions maintain a buy recommendation, demonstrating a certain confidence among analysts in the company's growth prospects. This increase in recommendations could positively influence investor interest in the stock.
“We continued to deliver strong commercial execution in Q3, and we achieved several meaningful scientific and regulatory milestones across our technology platforms.”
Commercial traction forte avec 40 systèmes ARC-EX vendus en Q3 et disponibilité dans plus de 60 cliniques US; CE Mark pour l'UE et clearance FDA pour usage à domicile élargissent l'opportunité commerciale; IDE approuvé pour ARC-IM permettant le lancement de l'étude pivot Empower BP; publications scientifiques majeures renforcent le dossier clinique.
Risks mentioned
retards dans les autorisations réglementaires
variations de la demande commerciale
concurrence technologique et concurrentielle
incertitudes liées aux études cliniques et résultats futurs
Opportunities identified
FDA clearance for home use expands US market opportunity
CE Mark enables commercialization in EU and facilitates entry to UK and Switzerland
IDE approval for ARC-IM enables initiation of Empower BP pivotal study
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
